The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | Is venetoclax appropriate for relapsed CLL patients?
Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK speaks about the latest therapies approved for chronic lymphocytic leukemia (CLL), and discusses the options for patients who relapse on these new therapies. Following resistance or intolerance to currently approved treatments, patients are in need of alternative options. Clinical trials have demonstrated that the administration of venetoclax has prolonged survival in these patients; however, there are not a lot of data on whether it is the correct drug to administer to patients who have been previously exposed to BCR inhibitors. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK.
